Herbalife grants interim CEO 34,593 stock-linked rights

The rights vest in three annual installments beginning November 4, 2027, subject to continued service, and expire November 4, 2036.

Available on EDGAR 11/06/2026 - 04:46 PM EST Accepted by SEC EDGAR 11/06/2026 - 04:46 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Herbalife Ltd. (HLF) interim CEO John DeSimone received a grant of 34,593 stock appreciation rights on November 4, 2026. The rights have a $15.31 exercise price and relate to 34,593 shares of common stock. They vest in one-third increments on November 4, 2027, November 4, 2028, and November 4, 2029, subject to continued service through each date; they expire November 4, 2036.

Insider Trade Summary

Grant/Award: 34,593 shares

Grant/Award 1 txn

Insider DeSimone John

Role Interim CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Appreciation Rights F1	34,593	$0.00	$0.00

Holdings After Transaction: Stock Appreciation Rights — 34,593 contracts (Direct)

Holdings Before and After: Stock Appreciation Rights, 0 to 34,593 contracts (Direct)

Footnotes (1)

1. F1. Consists of stock appreciation rights ("SARs") granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. These SARs will vest in one-third increments on each of November 4th, 2027, November 4th, 2028, and November 4th, 2029, subject to continued service through such date.

Key Figures

Stock appreciation rights granted: 34,593 rights Underlying common stock: 34,593 shares Exercise price: $15.31 per share +2 more

5 metrics

Stock appreciation rights granted 34,593 rights Granted November 4, 2026

Underlying common stock 34,593 shares Shares underlying the granted rights

Exercise price $15.31 per share For the stock appreciation rights

Vesting schedule One-third increments on November 4, 2027; November 4, 2028; and November 4, 2029 Subject to continued service through each date

Expiration date November 4, 2036 Stock appreciation rights

Key Terms

stock appreciation rights, Amended and Restated 2023 Stock Incentive Plan, vest

3 terms

stock appreciation rights technical

"Consists of stock appreciation rights"

Stock appreciation rights (SARs) are a form of employee compensation that give the holder the right to receive the increase in a company's stock price over a set baseline, paid in cash or shares, without having to buy the stock. For investors, SARs matter because they can create future cash outflows or share dilution and signal how a company rewards and motivates executives — similar to giving a bonus tied directly to how well the company’s stock performs.

Amended and Restated 2023 Stock Incentive Plan technical

"granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan"

vest technical

"will vest in one-third increments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock appreciation rights did HLF interim CEO John DeSimone receive?

John DeSimone received 34,593 stock appreciation rights on November 4, 2026, with a $15.31 exercise price. The rights vest in one-third increments on November 4, 2027, November 4, 2028, and November 4, 2029, subject to continued service through each date, and expire November 4, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeSimone John

(Last) (First) (Middle)

800 WEST OLYMPIC BLVD.

SUITE 406

(Street)

LOS ANGELES CALIFORNIA 90015

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HERBALIFE LTD. [ HLF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Rights	$15.31(1)	11/04/2026		A		34,593		(1)	11/04/2036	Common Stock	34,593	$0	34,593	D

Explanation of Responses:

1. Consists of stock appreciation rights ("SARs") granted under the Herbalife Ltd. Amended and Restated 2023 Stock Incentive Plan. These SARs will vest in one-third increments on each of November 4th, 2027, November 4th, 2028, and November 4th, 2029, subject to continued service through such date.

	/s/ Alaaeddine Sahibi, as Attorney-In-Fact for John DeSimone	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)